An observational study in Atherosclerotic Vascular Disease and Heterozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 20 sites in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Atherosclerosis by Novartis — 4 open to participants now, 10 under way, 3 of them phase 3. Atherosclerosis · Novartis.
Among the 27 studies in Atherosclerosis by Novartis, this one is one of 7 that started in 2025, is one of 8 observational ones, and was the 22nd registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →4 of the 27 studies in Atherosclerosis by Novartis are open now, in 5 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18–99
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–100
Novartis Pharmaceuticals · Sites in Russia
Ages 18–99
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
By country, each count listing its studies:
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 10 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is below the median of 250 across 526 observational studies indexed under Atherosclerosis.
Median enrollment 426 across the 18 interventional studies, 2,125 across the 8 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
6 of the studies in Atherosclerosis by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT07235046Novartis PharmaceuticalsA Study of DII235 in Adults With Elevated Lipoprotein(a) | 2027-04-26 |
| NCT06958315Novartis PharmaceuticalsInclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study | 2027-05-01 |
| NCT07034690Novartis PharmaceuticalsStudy to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 27 studies in Atherosclerosis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.
The objective of the study is to determine the proportion of Atherosclerotic cardiovascular disease (ASCVD) and/or Heterozygous Familial Hypercholesterolemia (HeFH) patients reaching low-density lipoprotein-cholesterol (LDL-C) goals according to their cardiovascular risk at 12 months after the initiation of inclisiran treatment.
The study also aims to evaluate changes in LDL-C levels, safety profile, adherence and persistence to inclisiran treatment, use of concomitant lipid-lowering therapy (LLT), and patient satisfaction with inclisiran among other variables collected in clinical practice.
This is a non-interventional, prospective, multicentric, and nationwide study that will be conducted in routine clinical practice in Spain. This study will consist of three visits, coinciding with those conducted as part of the patients' routine follow-up, without interfering with the clinical practice of the participating centers. A blood test to assess LDL-C levels will be conducted at 3, 6, 9 and 12 months after inclisiran initiation, according to clinical practice.
Adults (≥18 years) with a confirmed clinical indication for inclisiran.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Participating in a clinical trial of a treatment that could modify LDL-C levels during the observational period of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults (≥18 years) with a confirmed clinical indication for inclisiran.
Other: Inclisiran
This is an observational study, there is no treatment allocation.
Also known as: KJX839 Leqvio
LDL-C levels - 12 months
Proportion of participants reaching guideline-established low densitiy lipoprotein-Cholesterol (LDL-C) targets according to their Cardiovascular (CV) risk * LDL-C \<55 mg/dL for ASCVD participants. * LDL-C \<70 mg/dL for HeHF patients.
Time frame: 12 months following the initiation of inclisiran treatment.
LDL-C levels - 6 months
Proportion of participants reaching guideline-established LDL-C targets according to their CV risk * LDL-C \<55 mg/dL for ASCVD participants. * LDL-C \<70 mg/dL for HeHF patients.
Time frame: 6 months following the initiation of inclisiran treatment
non-HLDL-C levels
Proportion of participants with hypertriglyceridemia (triglycerides \>400 mg/dL) reaching guideline-established non-HDL-C targets according to their CV risk * Non-HDL-C \<85 mg/dL for ASCVD patients. * Non-HDL-C \<100 mg/dL for HeHF patients.
Time frame: 6 and 12 months following the initiation of inclisiran treatment
Changes from baseline in LDL-C
Change from baseline to mean LDL-C in PCSK9i naïve patients and patients pre-treated with PCSK9i, separately.
Time frame: Baseline, 3, 6, 9 and 12 months following the initiation of inclisiran treatment
Frequency of AEs
Incidence of AEs including, number of cardiovascular events, revascularizations, emergency visits, and hospitalizations qualifying and reported as AEs.
Time frame: From inclisiran initiation up to 12 months post-initiation
Adherence rate to the concomitant LLT treatment
Number of participants with a Morisky Medication Adjerence Slace (MMAS) of over 80%To describe the utilization and adherence to concomitant LLT during inclisiran treatment.
Time frame: From 1st visit up to 12 months after inclisiran initiation
Proportion of participants adhering to the prescribed inclisiran dosing schedule
To evaluate treatment adherence to inclisiran during the study period.
Time frame: From 1st visit up to 12 months after inclisiran initiation
Inclisiran reasons for non-persistence
Number of participants by reasons for non- persistence
Time frame: From 1st visit up to 12 months after inclisiran initiation
Lp(a)
Proportion of participants with Lp(a) ≥50 mg/dL (≥125 nmol/L), ≥70 mg/dL (≥175 nmol/L), ≥90 mg/dL (≥225 nmol/L).
Time frame: When available, from baseline up to 12 months after inclisiran initiation
Changes in Lp(a)
To describe changes in Lp(a) at any time after inclisiran treatment, only in patients tested by clinical judgment.
Time frame: From inclisiran initiation up to 12 months post-initiation
Patient satisfaction with inclisiran, score on TSQM-II
Treatment Satisfaction Questionnaire for Medication II evaluates satisfaction with treatment effectiveness, side effects, convenience, and global satisfaction. The TSQM-II consists of 11 items, each with 7 response options. Scores for each domain are calculated by averaging responses, transformed to a 0-100 scale, where higher scores indicate greater satisfaction
Time frame: 3 and at 12 months after treatment initiation.
Specialty of the health care profesional prescribing inclisiran
To describe prescribing specialty.
Time frame: From 1st visit up to 12 months after inclisiran initiation
HCP who administers inclisiran
To describe, HCP that administer inclisiran
Time frame: From 1st visit up to 12 months after inclisiran initiation
Site of treatment administration for each dose
To describe site of treatment administration (primary, secondary or tertiary hospital, primary care center)
Time frame: From 1st visit up to 12 months after inclisiran initiation
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.
Of 170 observational studies under Atherosclerosis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 153. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.